According to Moderna, the treatment would be almost 95% effective. Finally, the American biotech announces better conservation of its product.
Moderna intends to regain pole position from Pfizer in the race for the vaccine against Covid-19. A week just after the promising announcements of the American giant as to the effectiveness of its treatment developed with BioNtech, the American biotech led by Marseille-based Stéphane Bancel counter-attacks and publishes even more shocking preliminary results.
Moderna claims that its RNA Messenger vaccine candidate is 94.5% effective. This is better than the results presented by Pfizer. These results, also preliminary, come from its phase III clinical trial, “comprising more than 30,000 people” and carried out in the United States, “in association with the American Institute of Health (NIH) and Barda (the American authority for advanced R & D in the biomedical field, Editor’s note), ”the statement said.
1No cases of severe Covid observed
These results to be confirmed come after the follow-up of 95 cases of patients in the clinical trial infected with Covid-19. Of these, 90 were in the placebo group and only 5 in the one receiving Moderna’s vaccine candidate with the code name: mRNA-1273. The 95 contaminated participants include “15 people over 65 and 20 people from different communities” (Latinos, African-Americans, Americans of Asian origins, etc.).
Other striking information from these preliminary results: 11 cases of severe Covid have already been observed by Moderna during this phase III clinical trial. All took place in the placebo group. This seems to indicate that the vaccine candidate of the American biotech would fully protect against severe cases of infection. Finally, the preliminary analysis of the results confirms the safety of mRNA-1273 already observed during the two previous phases of the clinical trial.